Last reviewed · How we verify
Disgren (TRIFLUSAL)
Disgren (generic name: TRIFLUSAL) is a triflusal drug. It is currently in Phase 3 development.
Disgren works by inhibiting platelet aggregation through the inhibition of thromboxane A2 synthesis.
Triflusal is a small molecule used in clinical trials to study its effects on various conditions, including insulin resistance, atherothrombosis, and cerebral infarction. It has been tested in a randomized, placebo-controlled phase II crossover study to assess its influence on cognitive functions in healthy subjects.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | TRIFLUSAL |
|---|---|
| Drug class | triflusal |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Imagine your blood is made up of tiny cells called platelets that help your body stop bleeding when you get hurt. Disgren helps prevent these platelets from sticking together and forming clots, which can reduce the risk of heart attacks and strokes. This is done by blocking the production of a chemical called thromboxane A2, which is involved in the process of platelet aggregation.
Approved indications
Common side effects
Key clinical trials
- ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS) (PHASE4)
- Influence of Triflusal on Cognitive Functions in Subjects Under Chronic Stress (PHASE2)
- Influence of Triflusal on Cognitive Functions in Healthy Subjects (PHASE2)
- Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping (PHASE4)
- The Effect of Triflusal on Peripheral Microcirculation Dysfunction (PHASE4)
- Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Disgren CI brief — competitive landscape report
- Disgren updates RSS · CI watch RSS
Frequently asked questions about Disgren
What is Disgren?
How does Disgren work?
What is the generic name of Disgren?
What drug class is Disgren in?
What development phase is Disgren in?
Related
- Drug class: All triflusal drugs
- Therapeutic area: All drugs in Cardiovascular
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing